Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19

Parums, Dinah V.

doi:10.12659/msm.934393

Cited by 4 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estos esfuerzos se ilustran con REGEN COV, compuesto por dos anticuerpos monoclonales (imdevimab y casirivimab) con actividad neutralizante de SARs-CoV-2, con eficacia probada en situación de profilaxis pre-exposición y manejo ambulatorio de pacientes con alto riesgo. [2][3][4] Por las razones expuestas, este trabajo plantea demostrar la experiencia clínica de la Clínica Universitaria Unión Médica del Norte de República Dominicana, en uso compasivo de terapia inmunomoduladora mixta con base a REGEN COV, como una opción dual para tratamiento ambulatorio y base del tratamiento hospitalario.…”

Section: Introductionunclassified

Terapia de REGEN COV como base de terapia inmunomoduladora mixta en pacientes hospitalizados por neumonía por SARS-CoV-2: Serie de casos

2023

Respirar

View full text Add to dashboard Cite

Introducción: los países en desarrollo con sistema de salud de baja inversión encuentran un reto en priorizar el tratamiento de COVID-19 según su eficacia y sus costos. Materiales y métodos: se explora la utilidad hospitalaria de una intervención segura con eficacia ambulatoria comprobada. Se describe la administración de un tratamiento inmunomodulador combinado a base de imdevimab y casirivimab (REGEN COV). Resultados: los resultados individualizados apuntan a resultados prometedores en pacientes de alto riesgo a progresión y mortalidad. Conclusión: se ha demostrado que REGEN COV es eficiente para tratar dicha enfermedad. Sin embargo, se necesitan ensayos clínicos aleatorizados para comprobar su eficacia en combinación.

show abstract

Section: Introductionunclassified

Terapia de REGEN COV como base de terapia inmunomoduladora mixta en pacientes hospitalizados por neumonía por SARS-CoV-2: Serie de casos

2023

Respirar

View full text Add to dashboard Cite

show abstract

“…The drug data we have used here are those of monoclonal antibodies (mAbs). These have the capability to detect and prevent the disease propagation [36,37]. A SARS-CoV-2 patient who is at high risk of transmitting to another individual with SARS-CoV-2 for longer than 4 weeks, and who is unable to mount an adequate immune response to SARS-CoV-2 vaccination, can take an initial dose of 600 mg of casirivimab and 600 mg of imdevimab, then repeat doses of 300 mg of casirivimab and 300 mg of imdevimab once every 4 weeks [38].…”

Section: Introductionmentioning

confidence: 99%

Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy

Chatterjee

Basir

Biswas³

et al. 2022

Vaccines

View full text Add to dashboard Cite

Mathematical modeling is crucial to investigating tthe ongoing coronavirus disease 2019 (COVID-19) pandemic. The primary target area of the SARS-CoV-2 virus is epithelial cells in the human lower respiratory tract. During this viral infection, infected cells can activate innate and adaptive immune responses to viral infection. Immune response in COVID-19 infection can lead to longer recovery time and more severe secondary complications. We formulate a micro-level mathematical model by incorporating a saturation term for SARS-CoV-2-infected epithelial cell loss reliant on infected cell levels. Forward and backward bifurcation between disease-free and endemic equilibrium points have been analyzed. Global stability of both disease-free and endemic equilibrium is provided. We have seen that the disease-free equilibrium is globally stable for R0<1, and endemic equilibrium exists and is globally stable for R0>1. Impulsive application of drug dosing has been applied for the treatment of COVID-19 patients. Additionally, the dynamics of the impulsive system are discussed when a patient takes drug holidays. Numerical simulations support the analytical findings and the dynamical regimes in the systems.

show abstract

Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?

Zeng

2022

DDDT

View full text Add to dashboard Cite

The COVID-19 has plunged the world into a pandemic that affected millions. The continually emerging new variants of concern raise the question as to whether the existing vaccines will continue to provide sufficient protection for individuals from SARS-CoV-2 during natural infection. This narrative review aims to briefly outline various immunotherapeutic options and discuss the potential of clustered regularly interspaced short palindromic repeat (CRISPR Cas system technology against COVID-19 treatment as specific cure. As the development of vaccine, convalescent plasma, neutralizing antibodies are based on the understanding of human immune responses against SARS-CoV-2, boosting human body immune responses in case of SARS-CoV-2 infection, immunotherapeutics seem feasible as specific cure against COVID-19 if the present challenges are overcome. In cell based therapeutics, apart from the high costs, risks and side effects, there are technical problems such as the production of sufficient potent immune cells and antibodies under limited time to treat the COVID-19 patients in mild conditions prior to progression into a more severe case. The CRISPR Cas technology could be utilized to refine the specificity and safety of CAR-T cells, CAR-NK cells and neutralizing antibodies against SARS-CoV-2 during various stages of the COVID-19 disease progression in infected individuals. Moreover, CRISPR Cas technology are proposed in hypotheses to degrade the viral RNA in order to terminate the infection caused by SARS-CoV-2. Thus personalized cocktails of immunotherapeutics and CRISPR Cas systems against COVID-19 as a strategy might prevent further disease progression and circumvent immunity escape.

show abstract

Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19

Cited by 4 publications

References 14 publications

Terapia de REGEN COV como base de terapia inmunomoduladora mixta en pacientes hospitalizados por neumonía por SARS-CoV-2: Serie de casos

Terapia de REGEN COV como base de terapia inmunomoduladora mixta en pacientes hospitalizados por neumonía por SARS-CoV-2: Serie de casos

Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy

Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?

Contact Info

Product

Resources

About